Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component by Brot, Simone et al.
OR I G I N A L A R T I C L E
Histological and immunohistochemical investigation of canine
prostate carcinoma with identification of common intraductal
carcinoma component
Simone de Brot1,2 | Jennifer Lothion-Roy2,3 | Llorenç Grau-Roma1 |
Emily White2 | Franco Guscetti4 | Mark A. Rubin5,6 | Nigel P. Mongan3,7
1COMPATH, Institute of Animal Pathology,
University of Bern, Bern, Switzerland
2School of Veterinary Medicine and Science,
University of Nottingham, Nottingham, UK
3BioDiscovery Institute, University of
Nottingham, Nottingham, UK
4Institute of Veterinary Pathology, University
of Zurich, Zurich, Switzerland
5Department of BioMedical Research,
University of Bern, Bern, Switzerland
6Bern Center for Precision Medicine,
University of Bern and Inselspital, Bern,
Switzerland
7Department of Pharmacology, Weill Cornell
Medicine, New York, New York, USA
Correspondence
Simone de Brot, Institute of Animal Pathology,




Petplan Charitable Trust, Grant/Award
Number: 542127; University of Nottingham
Interdisciplinary Centre for Analytical Science
(UNICAS)
Abstract
A limited number of species, including men and dogs, spontaneously develop pros-
tate cancer (PC). The histological and molecular relevance of canine PC as a model
for the disease in men remains controversial. To address this challenge, this study
aimed to assess the histomorphology and expression of basal cell, urothelial and neu-
roendocrine markers [p63, high molecular weight cytokeratin (HMWCK), Uroplakin
3 (UPIII), neuron-specific enolase (NSE)] in canine PC (n = 41). Based on
histomorphology, 10/41 (24%), 21/41 (51%) and 9/41 (22%) were classified as ade-
nocarcinoma (AC), urothelial carcinoma (UC), and mixed carcinoma, respectively.
Tumour inflammation was common, frequently severe [20/41 (49%)], and associated
with neutering (p < .02) and urothelial differentiation (p < .02). Most (36/40, 90%)
cancers contained only rare cells with basal cell marker expression or were negative.
The expression of UPIII was absent or weak in the majority (33/38, 87%) of tumours,
with moderate to strong staining in the remaining cases. NSE expression in PC was
rare and limited to 2/14 (14%) cases. Tumour extension into benign ducts and glands
was a common finding with presence in 17/39 (44%) of carcinomas with and without
urothelial differentiation. In conclusion, we confirm that canine PC is characterized
by absent or weak expression of basal cell and urothelial markers. Although rare, NSE
expression, potentially indicating neuroendocrine differentiation, is reported for the
first time in canine PCa. Intraductal carcinoma of the prostate with concurrent inva-
sive PCa (IDCP-inv) is a frequent, not previously described, finding in dogs with PC.
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1 | INTRODUCTION
In men, prostate cancer (PC) is common occurring in one of every seven
men during their lifetime.1 This is in contrast to animals, which rarely
develop this malignancy spontaneously. In fact, only one animal species,
the dog, is known to develop PC on a regular basis.2–5 The dog has
therefore been nominated as an animal model for human PC.3,6–8
Canine PC is characterized by high tumour grade and aggressive
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biological behaviour with presence of metastasis in up to 40% of dogs
at the time of diagnosis.2,9 Prostate carcinoma (PCa) is the most com-
mon type of prostatic tumour,10 arising from glandular, ductal or ure-
thral epithelial cells. In men, urothelial cancers are distinguished from
PC. However, in canine PCa the cell of origin frequently remains
unknown.2,3,11,12 Despite certain limitations, such as commonly highly
aggressive disease with short survival times and androgen insensitivity,
pet dogs with spontaneous PCa are a promising and still underex-
ploited animal model.6 Spontaneous disease occurrence, similarities
in benign and neoplastic prostate anatomy and histology, shared
environment between men and dogs, utility for therapeutic studies
and the available canine genome sequence are some of the main
advantages, which the canine model can provide. Further investiga-
tions are needed in order to better evaluate the histological and
molecular relevance of canine PC as a model for the disease in men.
Prostate basal cell markers, including p63 and high molecular
weight cytokeratin (HMWCK), are routinely used for the diagnosis of
human PCa when assessing basal cell layer continuity.13–17 This how-
ever cannot be applied to dogs since the canine prostate basal cell
layer is discontinuous even in the benign gland.18,19 In most PCa of
men and dogs, the expression of basal cell markers is either absent or
restricted to a low number of neoplastic cells,19–21 with the exception
of one rare subtype of p63 positive PCa.19,21 P63 and HMWCK are
also used as urothelial markers, and may, ideally together with addi-
tional prostate glandular (PSA, PSAP, NKX3.1) and urothelial (GATA3,
CK7, CK20) markers, help to distinguish poorly differentiated human
glandular prostatic from urothelial carcinoma (UC).14,22–25 To our best
knowledge, the suitability of p63 and HMWCK for discriminating
between prostate glandular and urothelial carcinoma has however not
yet been examined in dogs.
UPIII, a highly specific but less sensitive marker for urothelial differ-
entiation, may be used in cases of human or canine PCa where UC is a
differential diagnosis.26–29 UPIII expression was demonstrated to be
common in canine PCa, leading to a suggested conclusion that canine
PCa may have its origin in the prostatic ducts based on the IHC expres-
sion pattern of eight different markers.11 To date, only a limited number
of studies report the expression of UPIII in canine prostate tissue.11,21
Neuroendocrine (NE) differentiation, that is, cells with NE mor-
phology and expression of NE markers, is an uncommon but relevant
feature of PCa due to its known association with tumour progression,
poor prognosis and an androgen receptor negative state.30–32 PCa
with NE differentiation is molecularly distinct from pure NE prostate
tumours. PCa cells are thought to become NE-like cells through trans-
differentiation even though the exact mechanism are only now being
deciphered.32,33 In benign canine prostates, the number of cells with
NE phenotype was observed to increase after castration, confirming
the association with androgen-independence in dogs.34 To date, stud-
ies reporting NE differentiation in canine PCa are lacking.
Intraductal carcinoma of the prostate (IDCP) refers to the presence
of prostate carcinoma cells within expanded, pre-existing non-neoplastic
prostatic ducts and acini.35,36 IDCP is has been classified as a separate
entity by the WHO 2016, comprising two distinct diseases: (i) IDCP
associated with invasive carcinoma (IDCP-inv) and (ii) pure IDCP. IDCP-
inv corresponds primarily to a growth pattern, whereas the latter is con-
sidered a rare precursor lesion of PCa.37,38 IDCP-inv is not uncommon
in men with invasive PCa and has been shown to be associated with
high tumour grade, advanced stage and poor disease outcome.39,40 Due
to its clinical relevance, pathologists are advised to record the presence
of this lesion. In canine PCa, the presence of IDCP has not been
reported and is described for the first time in the present study.
The aim of this study was to assess the histomorphology and
immunohistochemical expression of basal cell, urothelial and neuroen-
docrine markers in canine PCa, in comparison with non-neoplastic
prostate tissue.
2 | MATERIALS AND METHODS
2.1 | Samples
The protocol and procedures employed in this study were ethically
reviewed and approved by the Ethics committee at the University of
Nottingham School of Veterinary Medicine and Science (permission
number 1669 160 208). Formalin-fixed and paraffin-embedded
benign and malignant prostate tissue from 104 male dogs [n = 41 car-
cinoma, n = 17 normal glands, n = 15 benign prostate hyperplasia
(BPH), n = 16 glandular (n = 14 post-castration, n = 2 due to starva-
tion) atrophy, n = 14 neonatal or premature gland] was included. The
following case information was available: age at the time of prostate
tissue sampling/disease diagnosis, neutering status and dog breed. No
follow-up data was available. Within the PCa cases, the following
breeds were represented: n = 12 Labrador retriever, n = 5 cross
breeds, n = 24 various. All dogs with assessed benign gland were
intact except for 12 out of 14 cases with diffuse glandular atrophy.
Cases with cancer were either neutered (n = 24), entire (n = 7) or of
unknown neutering status (n = 10). The mean age (in years except for
neonatal/premature glands) of dogs belonging to the different groups
were as follows: neoplasia: 9.63 (SD 1.63); normal: 3.41 (SD 2.82);
hyperplasia: 8.07 (SD 2.56); atrophy: 8.53 (SD 4.17); neonatal/prema-
ture: 71 days (SD 67.13).
2.2 | Histology
Haematoxylin and eosin (HE)-stained tissue sections were histologi-
cally assessed by a board-certified veterinary pathologist (SdB), with
the support of two certified veterinary pathologists (LGR and FG), and
an experienced human uropathologist (MAR). As recently proposed by
Palmieri et al.,41 all tumours were classified based on their
histomorphology as: (1) prostatic urothelial carcinoma (UC); (2) pros-
tatic adenocarcinoma (AC); and (3) prostatic carcinoma with mixed
urothelial and glandular phenotypes. Based on their growth pattern,
UC were further subclassified as (i) solid, (ii) papillary or (iii) cribriform
and AC as (i) simple tubular, (ii) intra-alveolar (papillary, cribriform) or
(iii) solid. For each tumour, the mitotic activity was measured by cou-
nting the number of mitotic figures per 10 (or less in small tissue
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fragments) consecutive high-power fields (HPF) in the area of the
highest mitotic activity. The presence of inflammation was assessed in
all cancer cases and semi-quantified as follows (according to percent-
age of affected tissue): 0 = absent, 1 = mild (<5%), 2 = moderate (5–
50%), 3 = severe (>50%).
2.3 | Immunohistochemistry
Immunohistochemistry (IHC) of full tissue sections was performed for
p63 (n = 40 PCa, n = 60 non-neoplastic [n = 17 normal, n = 14 neona-
tal/premature, n = 13 BPH, n = 16 atrophy] prostates), UPIII (n = 39
PCa, n = 2 normal urinary bladder, n = 4 non-neoplastic prostate tissue
adjacent to carcinoma), as well as for few selected cases for the follow-
ing markers before staining tissue microarrays (TMA): CK5/6 (n = 2
PCa, n = 1 normal, n = 2 neonatal/premature prostates), CK14 (n = 2
PCa, n = 1 normal, n = 2 neonatal/premature prostates), and NSE
(n = 2 PCa, n = 1 normal, n = 2 neonatal/premature prostates). In addi-
tion, TMA [containing one to six 0.6 mm diameter tissue cores per case
of n = 45 PCa and n = 68 (n = 4 benign cancer-adjacent tissue, n = 13
neonatal/premature, n = 9 BPH, n = 22 normal, n = 11 prostatitis,
n = 9 atrophy) non-neoplastic prostates corresponding to the same
cases of which full tissue sections were assessed as indicated above]
were stained for CK5/6, CK14 and NSE. Information about the used
primary antibodies is given in Table 1. The antibodies (with the same
clones) used in this study were previously reported for the use in the
canine species.11,29,42–48 For UPIII, the antibody supplier confirms
cross-reactivity for canine tissue. Two to three μm paraffin-embedded
sections were mounted on positively charged slides (Colour Frosted
Plus, Biosystems, Muttenz, Switzerland), dried for 35 min at 60C and
subsequently dewaxed, pre-treated and stained on Bond-III
immunostainers (Leica Biosystems, Melbourne, Australia). After
dewaxing (Bond Dewax solution; Leica Biosystems), slides were subject
to a heat induced epitope retrieval step, using a Tris-EDTA (Bond Epi-
tope Retrieval 2; pH 9 for CK14, CK5/6, NSE, p63) and citrate based
buffer (Bond Epitope Retrieval 1, pH 6 for UPIII) for 20 to 40 min at
95 to 100C (Table 1). To reduce non-specific binding of primary anti-
bodies a protein block solution was applied for 10 min at room temper-
ature, as for all following steps. Then the slides were incubated with the
primary antibody for 15 min. All further steps were performed using
reagents of the Bond Polymer Refine Detection Kit (Leica Biosystems,
DS9800) as follows: Endogenous peroxidase was blocked for 5 (CK5/6,
CK14, NSE) to 10 (p63, UPIII) min, then a rabbit-anti-mouse secondary
antibody was applied (8 min), followed by a peroxidase-labelled polymer
(8 min). Both these reagents were supplemented with 2% dog serum to
block non-specific binding (LabForce, Nunningen, Switzerland). Finally,
slides were developed in 3,30-diaminobenzidine / H2O2 (10 min), coun-
terstained with haematoxylin, and mounted. In negative controls the
primary antibody was replaced with wash buffer. Known positive con-
trols were stained in parallel with each series.
The following semi-quantitative scoring system was used for p63,
CK5/6, CK14 and NSE: 0 = negative; 1 = rare (<5%) stained cells;
2 = moderate number (5–70%) of stained cells; 3 = large number (>70%)
of stained cells. For UPIII, staining intensity and distribution were scored
separately, using the following semi-quantitative system including staining
intensity and distribution. UPIII staining intensity was scored as 0 = nega-
tive; 1 = weak; 2 = moderate; 3 = strong. UPIII staining distribution
(according to percentage of stained neoplastic cells): 1 = multifocal,
<10%; 2 =multifocal, 10%–80%; 3 =multifocal to diffuse, >80%.
All PCa samples with available basal cell marker staining (40/41)
were assessed for the presence of intraductal or intraglandular carci-
noma spread (IDC) based on histomorphology and p63 staining. As
reported by Guo and Epstein39 IDC spread was defined as the pres-
ence of malignant epithelial cells filling large acini and prostatic
ducts, with preservation of basal cells and (i) solid or dense cribri-
form pattern or (ii) loose cribriform or micropapillary patterns with
marked nuclear atypia or comedonecrosis. IDC was not further clas-
sified as either UC with intraductal spread, or IDC of the prostate
(IDCP) with or without invasive carcinoma. If present, the IDC were
assessed for the following features: growth pattern (solid, dense
cribriform, loose cribriform or micropapillary), necrosis (present or
absent), extent of IDC as a percentage of the total tumour area
assessed (1: <10%, 2: 10%–49%, 3: 50%–90%, 4:>90%), and UPIII
staining (positive or negative).
2.4 | Statistical analysis
Statistics were performed using SPSS v.26.0 (IBM Corp., Armonk,
New York, USA). The Chi-square test was used to test for associations
TABLE 1 Primary antibodies used for immunohistochemistry
Antibody Clone Sourcea Code Dilution Pre-treatmentb
Cytokeratin 14 (CK14) LL002 Leica Biosystems NCL-L-LL002 1:150 H2(40)95
Cytokeratin 5/6 (CK5/6) D5/16B4 Dako (Agilent) M 7237 1:100 H2(30)100
Neuron Specific Enolase (NSE) MRQ-55 Cell Marque CMC30622000 1:100 H2(20)95
P63 DAK-p63 Agilent Technologies M731701-2 1:100 H2(30)99
UroplakinIII (UPIII) AU-1 Cell Marque 345 M-15 1:100 H1(30)99
aLeica Biosystems (Novocastra), Newcastle-upon-Tyne, UK; Dako, Glostrup, Denmark; Cell Marque, Rocklin, CA, USA; Agilent Technologies, Cheshire, UK.
bPre-treatment with Epitope Retrieval Buffer Type 1 (citrate based, pH 6) or 2 (Tris-EDTA based, pH 9) (Leica Biosystems) for (x) minutes at 95C, 99C or
100C on Bond-III immunostainers (Leica Biosystems, Melbourne, Australia).
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between the different clinical and histological parameters. p < .05 was
considered as significant.
3 | RESULTS
The examined cancerous prostate tissue was collected from dogs of
variable age, neutering status and breed (Table 2). Most cases were
seen in Labrador retrievers (12/41, 29%) and cross breeds (5/41,
12%), presumably representing two of the most common breeds in
the UK (https://www.thekennelclub.org.uk/, accessed 6 May 2020).
Based on histomorphology, 10/41 (24%), 21/41 (51%) and 9/41
(22%) were classified as AC, UC, and mixed carcinoma, respectively
(Table 2). One case of UC presented with extensive squamous differ-
entiation. Two of the tumours classified as mixed carcinoma were
assigned to this group due to a lack of convincing either glandular or
urothelial features. Instead, they were characterized by a diffusely
anaplastic or squamous morphology. One case could not be classified




















































































































































































































































































































































































































































































































































































































































































































F IGURE 1 Canine prostate carcinoma with predominantly
cribriform growth, classified as mixed glandular and urothelial
carcinoma. Haematoxylin and eosin (HE) stain. Bar indicates 200 μm.
Inset. Same case depicting an area with a different, more anaplastic
(solid) growth pattern. HE stain. Bar indicates 200 μm
F IGURE 2 Poorly differentiated, suspected primary glandular,
canine prostate carcinoma. Neoplastic cells appear anaplastic and a
highly discohesive growth is evident. HE stain. Bar indicates 100 μm.
Inset: Same case at higher magnification. HE stain. Bar
indicates 50 μm
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further classified as simple tubular (5/10; 50%), intra-alveolar (3/10;
30%) and solid (2/10; 20%), whereas all UC were cribriform
(Figures 1-3) (Table 2). No neuroendocrine morphology, neither focal
nor diffuse, was observed in any of the assessed tumours. The mitotic
activity varied markedly between the individual carcinomas, with 0–
74, 0–43 and 0–49 mitotic figures per 10 HPF for UC, AC and mixed
carcinomas, respectively. The mean number of mitotic figures per
HPF was similar in all three carcinoma subtypes, with 1.33 (SD 1.75),
1.44 (SD 1.48) and 1.90 (SD 1.99) mitoses for UC, AC and mixed carci-
nomas, respectively. No significant differences in the mitotic count
was observed between UC and non-UC tumours.
All but two (39/41, 95%) of PCa were accompanied by a certain
degree of inflammatory reaction, which was severe in 20/39 (51%),
moderate in 8/39 (21%), and mild in 11/39 (28%) of cases (Table 2).
The inflammation typically comprised a multifocal to coalescing
lymphoplasmacytic infiltrate (Figure 4). The presence of moderate to
severe inflammation was more common in neutered (19/24, 79%)
compared with entire dogs (2/7, 29%) (p < .02). Due to the small
sample size and Cramer-V value of 0.453, the effect size however
was considered only moderate. The same association with the pres-
ence of moderate to severe inflammation was true for dogs with UC
(18/21, 86%) compared with non-UC (10/20, 50%) (p < .02). When
comparing dogs with UC versus non-UC, neutering was significantly
more common in the UC group (15/15, 100% versus 9/16, 56%)
(p < .005). No significant age differences were observed between
UC and glandular PCa or between entire and neutered dogs,
respectively.
IHC staining for p63 and HMWCK (i.e., CK5/6 and CK14) in
benign prostate glandular tissue was limited to basal cells. In normal
and hyperplastic glands, the basal cell layer was discontinuous,
whereas neonatal/premature glands presented with a continuous
layer of basal cells. In atrophic glands, a mixture of continuous and, to
a lesser extent, discontinuous basal cell layers were observed. The
urothelium lining prostate ducts and the urethra showed consistent
p63 and CK5/6 staining of basal and intermediate cells. However, a
multifocally discontinuous layer of stained basal cells was seen in dis-
tal non-urothelial portions of the duct. In contrast to p63 and CK 5/6,
CK14 was less sensitive with only rare staining of basal and urothelial
cells. In premature glands, CK5/6 stained basal cells were restricted to
the duct-acinar transition area and outermost peripheral acini and
CK14 staining was negative altogether.
P63 staining was performed in 40/41 PCa cases and was pre-
sent in 24/40 (60%). It was characterized by a consistently strong
nuclear signal in a varying number of neoplastic cells. Twenty out of
40 (50%) PCa had rare (<5%), individual p63 positive cells (Figure 5),
16/40 (40%) lacked p63 expression, and 4/40 (10%) demonstrated
p63 positivity in >70% of neoplastic cells. Moderate p63 staining
(5%–70% positive cells) was not observed. The four cases with high
p63 expression consisted of two well-differentiated carcinomas, his-
tomorphologically interpreted as urothelial, and two (one classified
as urothelial and one as mixed) carcinomas with squamous differen-
tiation. In the two cases with urothelial morphology, p63 staining
was restricted to basal and intermediate epithelial cells. In a large
proportion of PCa (17/39, 44%), neoplastic cells were observed
F IGURE 3 Urothelial carcinoma in the canine prostate gland.
Neoplastic nests are embedded in a severely inflamed stroma. HE
stain. Bar indicates 200 μm. Inset: UPIII immunohistochemistry of the
same case with moderate apical membranous staining. Bar
indicates 200 μm
F IGURE 4 Canine prostatic carcinoma with mixed urothelial and
glandular morphology. Two different growth patterns are evident,
consisting of more basaloid appearing, suspected squamous (*), and
cribriform (**) areas. Note the markedly inflamed tumour stroma. HE
stain. Bar indicates 100 μm
F IGURE 5 P63 immunohistochemistry of an urothelial carcinoma
with cribriform growth pattern in the canine prostate gland. A low
number of neoplastic cells show strong nuclear staining. Bar indicates
200 μm. Inset: UPIII immunohistochemistry of the same case and
region with weak apical membranous staining. Bar indicates 200 μm
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intraluminally in variably expanded non-neoplastic ducts and glands,
with preserved p63 stained basal cell layers, compatible with intra-
ductal or intraglandular carcinoma (IDC) spread (Figure 6) (Table 3).
Despite discontinuity of the remaining basal cell layer, as seen in
benign canine prostate glands, this layer was interpreted to be pre-
served due to the absence of neoplastic proliferations breaking
through basal cell lining. The extent of IDC within the examined
tumour area was less than 10% in most cases (11/17; 65%), whilst in
2/17 (12%), 3/17 (18%) and 1/17 (6%) of cases, IDC took up 10%–
49%, 50%–90% and > 90% of the tumour section, respectively. IDC
growth was predominantly solid (11/17, 65%), with a dense cribri-
form pattern in the remaining cases (6/17, 35%). Necrosis within
IDC was an uncommon feature (2/17, 12%). The majority (13/17;
76%) of tumours with IDC corresponded to UC. In these cases, IDC
remained UPIII negative in 6/13 (46%), with weak, moderate or
strong UPIII staining in 3/13 (23%), 2/13 (15%) and 2/13 (15%),
respectively. IDC spread was associated with the presence of mod-
erate to severe tumour inflammation (15/17, 88% versus 2/17,
12%) (p < .03).
CK5/6 and CK14 expression was limited to 4/18 (22%) PCa. One
of these cases was characterized by diffuse squamous differentiation,
with strong expression of CK5/6, CK14 and p63. The three other
cases were multifocally CK14 positive in regions with squamous dif-
ferentiation with a lack of CK5/6 and minimal to absent p63 and UPIII
expression. Based on histomorphology, the CK14 positive areas were
found to correspond to regions with squamous differentiation.
F IGURE 6 Intraductal and intraglandular tumour spread in the canine prostate corresponding to a case of intraductal carcinoma of the
prostate with concurrent invasive carcinoma with mixed urothelial and glandular morphology (A,B) and a case of urothelial carcinoma with
cribriform growth pattern (C). Intraductal and intraglandular tumour extension is evident with remaining p63 positive benign basal cells of pre-
existing ducts and glands (B,C). A: HE stain. Bar indicates 500 μm. (B,C): P63 immunohistochemistry. Bar indicates 500 μm





Extent of IDCa Growth pattern of IDC
Presence of
necrosis in IDC1 2 3 4 Solid Dense cribriform
PCa
(AC or mixed carcinoma)
4/18 (22%)
• 2/9 (22%)b AC
• 2/9 (22%) mixed
1/4 (25%) 1/4 (25%) 2/4 (50%) 0/4 2/4 (50%) 2/4 (50%) 2/4 (50%)
UC 13/21 (62%)c 10/13 (77%) 1/13 (8%) 1/13 (8%) 1/13 (8%) 9/13 (69%) 4/13 (31%) 0/13
Total 17/39 (44%) 11/17 (65%) 2/17 (12%) 3/17 (17%) 1/17 (6%) 11/17 (65%) 6/17 (35%) 2/17 (12%)
Abbreviations: AC, adenocarcinoma; IDC, intraductal carcinoma spread; PCa, prostate carcinoma; UC, urothelial carcinoma; UPIII, UroplakinIII.
a1: <10%; 2: 10%–49%; 3: 50%–90%; 4: >90% of assessed total tumour tissue.
bIn one case, the presence of IDC could not be assessed due to missing basal cell (p63) staining.
cp < .05 (Chi-square test).
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Expression of UPIII was assessed in 38/41 PCa. It was charac-
terized by a variably intense membranous staining, which was most
pronounced along luminal surfaces. UPIII staining was negative in
22/38 (58%) of cases and showed a weak (11/38, 29%), moderate
(4/38, 11%), or strong (1/38, 3%) staining intensity (Figure 7). The
distribution and percentage of stained cells was rare (<10% of cells)
in 12/16 (75%) of cases, multifocal (10–80% of cells) in 2/16 (13%),
and multifocal to diffuse (>80% of cells) in 2/16 (13%). When com-
paring the histomorphological diagnosis and UPIII staining, 14/21
(67%) UC stained positive with weak, moderate and strong staining
intensities in 9/14 (64%), 4/14 (29%) and 1/14 (7%) of cases,
respectively. UC with weak staining intensities presented with <10%
of UPIII positive cells, whereas the one case with strong staining
showed >80% of UPIII stained cells. The number of UPIII positive
cells in UC with moderate staining intensities varied markedly, rang-
ing from <10% (n = 1), 10%–80% (n = 2) to >80% (n = 1) of sta-
ined cells. All but one case of AC remained UPIII negative. The
single AC case with strong UPIII staining was characterized by
severe autolytic and freezing tissue artefacts and additional strong
UPIII positivity in non-urothelial epithelial cells in the lungs and
kidney. UPIII staining in mixed (glandular and urothelial) carcinomas
was limited to 2/9 (22%) cases, which showed weak staining of
<10% of cells in areas with urothelial morphology. In non-neoplastic
prostate tissue, duct as well as urethra demonstrated apical mem-
branous UPIII staining. The co-expression of basal cell markers and
UPIII could be assessed in 37/41 cases. Results are provided in
Table 4. Double negative PCa were most common (12/37, 32%),
followed by PCa with weak UPIII and rare p63 staining (7/37, 19%).
The four PCa cases with strong p63 expression did not express
UPIII.
Immunohistochemical expression of NSE was observed in two
PCa. The first case, with available IHC staining of the full tumour tis-
sue cross section, presented with multifocal cytoplasmic staining of
approximately 5%–10% of tumour cells with a variable, weak to
strong staining intensity (Figure 8). This case corresponded to a pri-
mary acinar adenocarcinoma with multifocal mucoid and cystic mor-
phology. The second case, where IHC staining was restricted to one
tissue core within the TMA, was characterized by weak to moderate
cytoplasmic NSE expression in >90% of neoplastic cells. This case cor-
responded to a UC with strong UPIII staining.
F IGURE 7 UroplakinIII
immunohistochemistry of three different
histomorphologically classified as
urothelial carcinomas in the canine
prostate, characterized by a variably
intense, multifocal, apical membranous
staining of neoplastic cells. Moderate
(A) (same case as shown in Figure 3), weak
(B) (same case as shown in Figure 5) and
strong (C) staining
TABLE 4 Combined p63, HMWCK
and UroplakinIII immunohistochemical
staining of 37 canine prostate carcinomas P63/HMWCK
No of cases showing indicated UroplakinIII staining result
TotalNegative Weak Moderate Strong
Double negative
P63/HMWCK 12a 3 0 0 15
Rare p63 positivityb
P63+//HMWCK 6 7 4 1 18
Double positivec
P63+/HMWCK+ 4d 0 0 0 4
Total 22 10 4 1 37
aOne case with multifocal CK14 expression (P63/CK5/6/CK14+).
b<5% p63 positive cells.
c>70% p63 positive cells.
dOne case with negative CK14 and not performed CK5/6 staining (P63+/CK14).
DE BROT ET AL. 7
4 | DISCUSSION
Even though less common than in men, PC occurs spontaneously and
commonly in dogs.2–5 The cell of origin remains unknown in many
cases of canine PC, primarily due to the indistinguishable
histomorphology of advanced disease at the time of diagnosis. Whilst
the prognostic significance of the different histologic canine tumour
subtypes remains largely unknown, there is a tendency for a higher
metastatic rate in cancers with a mixed morphology.2 In addition,
knowing the histogenesis of canine PC is crucial when considering
using PC in the dog as a spontaneous animal model for PC in men as
has been suggested in several occasions.3,6–8 When comparing UC
versus primary glandular or mixed glandular and urothelial PCa, the
present study shows a higher ratio of neutered dogs in UC compared
to non-urothelial tumours. Similar findings have been described in a
study with 76 dogs, which reported a higher risk of prostate adeno-
carcinoma in entire dogs compared with carcinomas with a mixed
(including urothelial) morphology.2
Canine PCa is further classified as (i) prostatic UC; (ii) prostatic
AC; and (iii) prostatic carcinoma with mixed urothelial and glandular
phenotypes, based on the histomorphological appearance.3,49,50
Poorly differentiated PCa are not uncommon in dogs, making the
histomorphological distinction between AC and UC difficult. In
the present study, 9 out of 41 (22%) PCa were histomorphologically
classified as mixed glandular and urothelial carcinomas. Two of these
tumours were assigned to this group due to the absence of convincing
either glandular or urothelial features. Instead, they appeared diffusely
anaplastic or had a diffuse squamous morphology, which did not allow
distinction between UC and AC.
The role of IHC as diagnostic tool remains controversial, espe-
cially since some canine PCa may express both urothelial and glandu-
lar prostate markers, such as PSA, PSMA, UPIII, CK5, CK7, CK14 and
CK18.2,3,11,51 Uroplakin, a transmembrane protein expressed by apical
urothelial (umbrella) cells, is known to be a specific marker for terminal
urothelial differentiation in both men and dogs,27,29 however its sensi-
tivity is often only in the range of 40%–60%.27,41,52–54 In a study of
90 canine PCa, 47 cases expressed UPIII,15 with similar results in a
previous work by Lai et al.11 Based on the staining with UPIII and
other markers, Lai et al.11 proposed that canine PCa may derive from
prostatic ducts rather than from acini. Similarly, to the previously
reported findings, a significant proportion (17/41, 41%) of all PCa
expressed UPIII in the present study. The majority (14/17, 82%) of
UPIII positive tumours corresponded to UC, confirming the specific
staining of this marker, as reported previously.28,54 One third of UC
and most of the mixed carcinomas were UPIII negative, which was an
expected finding due to the previously reported moderate sensitivity
of this marker.27,52–55 All but one case of AC remained UPIII negative.
The UPIII positive staining in one AC was considered artefactual due
to the presence of severe post-mortem tissue changes in this case.
We confirm that UPIII is highly specific for urothelial differentiation
and that convincing membranous UPIII staining is restricted to the
urethra and proximal ducts in the benign canine prostate.
P63, which belongs to the p53 family,56 is one of basal cell, as well
as urothelial cell, markers when diagnosing PCa in men. In this setting,
its two main purposes are: (i) as a basal cell marker, to help to distin-
guish neoplastic from non-neoplastic prostate tissue by assessing the
continuity of the glands' basal cell layer,15–17 and (ii) as a marker for
urothelial differentiation, to aid in the differentiation between poorly
differentiated adenocarcinoma and high-grade UC.22–24,57,58 In dogs,
the first aim of p63 immunodetection is not directly applicable since
the basal cell layer in the healthy canine prostate gland is
discontinuous,18,19 which has been confirmed in the present study. In
men, p63 immunodetection is known to be highly specific and moder-
ately sensitive for UC, when compared to primary glandular PCa.22,23
To date, the specificity and sensitivity of p63 for urothelial differentia-
tion in dogs with PCa has not been reported. In the few available
canine studies which evaluated p63 in PCa, the tumours were charac-
terized by rare or absent expression of p63,19–21 with the exception
of a very rare subtype of glandular PCa, which aberrantly expresses
p63.21 In the canine cases of the present study, p63 expression was
limited to rare (<5%) cells in most (90%) PCa, which is in agreement
with previous studies.20 The remaining four cases, consisting of two
PCa with squamous differentiation and two well differentiated,
suspected UC, were characterized by strong expression of p63. The
two cases with squamous morphology most likely represent UC with
squamous differentiation, which is common in canine and human
UC.1,59,60 The differential diagnosis of primary prostate squamous cell
carcinoma cannot be ruled out, but is considered less likely due its rare
occurrence.59 While squamous cell carcinomas are well known to
express p63 in both men and dogs,3,61,62 little is known about the level
of p63 expression in canine urothelial tumours. In a study including
25 dogs with bladder UC, p63 has been shown to be rarely detected
in neoplastic cells, in contrast to a strong expression in urothelial cells
of normal and inflamed bladder tissue.63 As far as the authors are
aware, canine studies comparing p63 expression between urothelial
and primary glandular PCa are lacking.
When combining the basal cell markers (p63, HMWCK) and UPIII
staining, most PCa were either triple negative or weakly positive in
the present study. In triple negative PCa, UC cannot be excluded with
F IGURE 8 Primary glandular canine prostate carcinoma with
evident papillary growth. HE stain. Bar indicates 500 μm. Inset: Same
case with IHC staining of neuron-specific enolase. Multifocal weak to
moderate cytoplasmic staining of tumour cells is present.
Immunohistochemistry. Bar indicates 50 μm
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certainty since these markers have limited sensitivities and because
poorly differentiated human and canine urothelial or non-urothelial,
PCa are known to have only rare or absent expression of these
markers.19,20,64 Considering the known high specificity of UPIII, it can
be assumed that UPIII positive tumours or tumour areas correspond
to urothelial differentiation. Interestingly, the two cases comprising
relatively well differentiated neoplastic urothelium with strong p63
expression were UPIII negative. Based on histomorphology, these two
cases were suggestive of UC even though a ductal or, less likely, glan-
dular origin could not be ruled out with certainty. The six UPIII nega-
tive cases with rare p63 and absent HMWCK expression are difficult
to interpret and cannot be further classified as either urothelial or pri-
mary glandular PCa. Finally, all cases with moderate or strong UPIII
expression, which convincingly represent UC, were only p63 positive
in a low number of cells and were negative for HMWCK. In the exam-
ined canine prostate UC, higher expression of UPIII does not, there-
fore, appear to correspond to higher p63 expression. In fact, a
previous study reported that only p63 negative tumour cells
expressed UPIII.64 It was proposed that loss of p63 is required for ter-
minal urothelial differentiation, in both normal as well as neoplastic
urothelium. To the authors' best knowledge, studies evaluating the
combined staining pattern of UPIII and p63 in canine PCa are lacking.
CK5/6 and CK14 expression was absent in all but four canine
PCa. One UPIII negative PCa with diffuse squamous differentiation
was strongly positive for CK5/6 and CK14, as well as p63. This is an
expected finding since all three are squamous specific markers for
human and canine tissue.65–67 Three further cases were multifocally
CK14 positive with lack of CK5/6 and absent or minimal p63 and
UPIII expression. In these cases, CK14 positive tumour areas were
interpreted to correspond to regions with squamous differentiation.
None of the UPIII positive PCa showed any expression of CK5/6. This
may seem surprising as both markers are known to reliably stain a sig-
nificant proportion of UC.25,67 However, false CK5/6 negative cases
are considered likely due to the following reasons: i) UPIII expression
was only weak and restricted to less than 10% of the tumour tissue
section in the majority of cases and ii) CK5/6 staining was performed
on TMAs, representing only a small fraction of the entire tumour. In
contrast to p63, multifocal staining of low numbers of individual neo-
plastic cells was not observed for HMWCK.
In benign, that is, normal as well as hyperplastic, canine prostates
examined in the present study, basal cell staining confirmed the previ-
ously reported discontinuous basal cell layer in dogs.18–20 In contrast
to p63 and CK5/6, IHC for CK14 revealed only rare staining of basal
cells. Previous studies, which used a CK14 antibody with the same
clone (LL002) report similar observations, with either absent or rare
CK14 expression in basal cells of benign dog glandular prostate tis-
sue.11,42,45 This is in contrast to the benign human gland where CK14
positive basal cells are prominent.68 Given the lack of CK14-positive
cells and comparably low number of CK5-positive basal cells, the
canine prostate is considered to have a more differentiated pheno-
type compared to the same gland in men.42
In the still developing post-natal canine prostate, the basal cell
layer is known to be continuous until shortly after puberty,18 which
was confirmed in the present study. Interestingly, the currently exam-
ined canine premature glands presented with a diffuse p63 staining of
basal cells whereas the CK5/6 basal cell staining was restricted to the
duct-acinar transition area and outermost peripheral acini. This spe-
cific CK5/6 staining pattern was interpreted to correspond to a dis-
tinctive basal cell differentiation and proliferation program, which was
previously shown to spread radially from the urethra to the peripheral
acini.18 In human prostates, a similar well-defined pattern of radial dif-
ferentiation of the epithelial cords is reported.49,69,70
In men, there is evidence that inflammation can initiate the neo-
plastic process.71 The presence of stromal inflammatory cells in
benign as well as malignant human prostate glands is a common find-
ing.71 This was confirmed in the examined canine PCa which pres-
ented with a frequent and often severe stromal inflammatory
reaction. Interestingly, the inflammation was more severe in UC com-
pared to AC or mixed (glandular and urothelial) PCa. Similar findings
have been published in men, with stromal inflammation more common
in UC compared to glandular PCa.1
A large proportion (44%) of the studied canine PCa showed intra-
ductal or intraglandular carcinoma (IDC) spread. The extent of IDC
within the examined tumour area was less than 10% in most (65%)
cases. The predominant IDC growth pattern was solid in the majority
of cases, and necrosis within IDC was uncommon. Based on the
histomorphology, the majority of the examined PCa with IDC were
suspected to represent UC, corresponding to UC with intraductal
spread, as reported by Wobker et al.36 IDC was, however, also
observed as a concurrent feature of invasive PCa in some of the pri-
mary glandular non-urothelial carcinomas studied in the present
canine cohort. In men, this phenomenon is referred to as intraductal
carcinoma of the prostate (IDCP) with invasive carcinoma (IDCP-
inv).1,38,39,72 IDCP (with or without concomitant invasive carcinoma)
in men is defined as malignant epithelial cells filling large acini and
prostatic ducts, with preservation of basal cells and (i) solid or dense
cribriform pattern or (ii) loose cribriform or micropapillary pattern with
either marked nuclear atypia (nuclear size 6  normal or lager) or non-
focal comedonecrosis.39 Additional but not required diagnostic minor
criteria have been described, including number of affected glands,
irregular glandular branching and mitotic activity among others.72 In
the present study, high-grade prostatic intraepithelial neoplasia
(HGPIN) was considered as a differential diagnosis for IDC-P as well
as for intraductal spread of UC. Due to the predominantly solid
growth pattern, which is absent in HGPIN,39 and the frequently highly
pleomorphic neoplastic cells, HGPIN was however considered
unlikely. Whilst IDCP-inv is a yet undescribed entity in dogs, or any
other animal species that develops spontaneous PC, the
histomorphology of this entity in men closely resembles the same fea-
ture in the herein examined canine tissues. Considering the typically
aggressive behaviour and advanced disease stage at diagnosis of PC
in dogs, the presence of IDCP-inv and its association with poor prog-
nosis and advanced tumour stage is not an unexpected finding. The
present study also confirms for dogs the known challenge in men to
histomorphologically distinguish IDCP from UC with intraductal
spread.36,39
DE BROT ET AL. 9
Neuroendocrine differentiation was rare in the studied canine PCa
and only suspected based on the IHC expression of NSE, without con-
vincing evidence of characteristic NE histomorphology. The NSE
staining requires cautious interpretation for the following reasons: i)
NSE should not be used as a sole marker for NE differentiation due to
its limited specificity,73 and ii) false negative cases are possible since
NSE staining was only performed on TMA, representing only a minor
portion (one 0.6 mm diameter core) of the total tumour volume. NSE
expression was limited to one case each of primary glandular and of
urothelial carcinoma. NE differentiation is known to occur in as many as
10% of PCa but is rarely described in UC of men.74,75 This feature
becomes more extensive following androgen deprivation therapy and
with cancer progression.76 To date, NE differentiation has however not
yet been described in canine prostate tumours. In order to confirm NE
differentiation in the studied cases, further investigation with more spe-
cific NE (i.e., chromogranin, synaptophysin) markers is needed.
In conclusion, the examined canine PCa were characterized by
poor differentiation, which made the histomorphological distinction
between urothelial and primary glandular carcinomas difficult. Most
canine PCa showed absent or weak expression of basal cell and
urothelial markers. Tumour inflammation was common, typically
multifocal to coalescing, lymphoplasmacytic and frequently severe.
Extensive inflammation was significantly more common in neutered
compared with sexually intact dogs and more frequent in PCa with
urothelial differentiation. Although rare, NSE expression, potentially
indicating neuroendocrine differentiation, is reported for the first time
in canine PCa. Intraductal or intraglandular tumour spread of both pri-
mary glandular as well as urothelial PCa was a common finding. In
non-urothelial PCa, intraductal spread corresponds to an intraductal
carcinoma of the prostate with concurrent invasive PCa (IDCP-inv),
which is described for the first time in dogs with PC. In summary,
canine PC is characterized by frequent intraductal and intraglandular
tumour spread, stromal inflammation and weak to absent expression
of basal and urothelial cell markers.
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